Latest dermatitis Stories
Nine scientists receive funds to study psoriatic disease PORTLAND, Ore., April 11, 2011 /PRNewswire-USNewswire/ -- The National Psoriasis Foundation awarded $750,000 in nine research grants to the nation's leading scientists studying psoriasis--a chronic disease of the immune system that appears on the skin, affecting as many as 7.5 million Americans--for projects with the highest likelihood of resulting in better treatments and a cure for this disease.
LUXEMBOURG, March 10, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology.
SAN FRANCISCO, Feb. 16, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Oculus Innovative Sciences, Inc., (Nasdaq: OCLS) and maintains its $3.81 target price.
OXFORD, England, February 9, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales. PAP-1 is one of the most potent...
Preventative tips may help minimize risks NEW ORLEANS, Feb.
New guidelines stress the need for proper diagnosis to confirm allergy NEW ORLEANS, Feb. 4, 2011 /PRNewswire-USNewswire/ -- Atopic dermatitis, one of the most common forms of eczema in this family of inflammatory skin diseases, is a chronic disease marked by red, cracked and itchy skin.
KVISTGARD, Denmark, February 1, 2011 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that it has completed a clinical Phase 2 trial of its smallpox vaccine, IMVAMUNE(R), in individuals suffering from atopic dermatitis (a.k.a. eczema).
Like a fence or barricade intended to stop unwanted intruders, the skin serves as a barrier protecting the body from the hundreds of allergens, irritants, pollutants and microbes people come in contact with every day.
LUXEMBOURG, December 15, 2010 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis. CT327 is a novel topically applied TrkA kinase inhibitor developed using the Creabilis' LSE (Low Systemic Exposure) technology.
'Pruritic nodules' are small lumps under the skin that cause itching and which, according to some studies, can remain for several years.